CN Patent

CN102458581A — 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物

Assigned to Because of C1-esteraseremmer-N parent corporation · Expires 2012-05-16 · 14y expired

What this patent protects

本发明涉及式I的N-(杂)芳基-吡咯烷衍生物：其是诸如选择性JAK1抑制剂的JAK抑制剂，其用于治疗JAK-相关疾病，包括例如炎症性和自身免疫性疾病以及癌症。

USPTO Abstract

本发明涉及式I的N-(杂)芳基-吡咯烷衍生物：其是诸如选择性JAK1抑制剂的JAK抑制剂，其用于治疗JAK-相关疾病，包括例如炎症性和自身免疫性疾病以及癌症。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN102458581A
Jurisdiction: CN
Classification: —
Expires: 2012-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Because of C1-esteraseremmer-N parent corporation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.